Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Clinical trial NCT06358573 · RECRUITING
Trial details
- NCT number
- NCT06358573
- Sponsor
- Swiss Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-24
- Primary completion
- 2028-10-01
- Enrollment
- 61
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.